{
    "nct_id": "NCT06610825",
    "official_title": "A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fam-Trastuzumab Deruxtecan-Nxki (T-DXd) as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma",
    "inclusion_criteria": "* Pathologically confirmed adenocarcinoma of the prostate\n* Diagnosis of mCRPC\n* Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen\n* Ongoing ADT to maintain serum testosterone levels below 50 ng/dL\n* Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry\n* Life expectancy 6 months\n* ECOG 0 or 1\n* LVEF at least 50%\n* Adequate Blood Clotting function\n* Adequate Organ and Bone Marrow function\n* Adequate Renal function\n* Adequate Hepatic function\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of interstitial lung disease or pneumonitis requiring steroids\n* Significant coronary vascular disease\n* Previous exposure to HER2 targeted therapy",
    "miscellaneous_criteria": ""
}